Where Will Neoleukin Therapeutics Inc (NLTX) Stock Go Next After It Has Risen 25.49% in a Week?

Friday, March 10, 2023 12:59 PM | InvestorsObserver Analysts

Mentioned in this article

Where Will Neoleukin Therapeutics Inc (NLTX) Stock Go Next After It Has Risen 25.49% in a Week?

Overall market sentiment has been high on Neoleukin Therapeutics Inc (NLTX) stock lately. NLTX receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Neoleukin Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on NLTX!

See Full NLTX Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With NLTX Stock Today?

Neoleukin Therapeutics Inc (NLTX) stock is trading at $0.64 as of 12:57 PM on Friday, Mar 10, a drop of -$0.08, or -11.11% from the previous closing price of $0.72. The stock has traded between $0.64 and $0.70 so far today. Volume today is high. So far 726,567 shares have traded compared to average volume of 534,172 shares. To see InvestorsObserver's Sentiment Score for Neoleukin Therapeutics Inc click here.

More About Neoleukin Therapeutics Inc

Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. Click Here to get the full Stock Report for Neoleukin Therapeutics Inc stock.